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Constitutive resistance to cell death induced by inflammatory stim-
uli activating the extrinsic pathway of apoptosis is a key feature of
vascular endothelial cells (ECs). Although this property is central to
the maintenance of the endothelial barrier during inflammation,
the molecular mechanisms of EC protection from cell-extrinsic,
proapoptotic stimuli have not been investigated. We show that
the Ig-family member CD31, which is expressed by endothelial
but not epithelial cells, is necessary to prevent EC death induced
by TNF-α and cytotoxic T lymphocytes in vitro. Combined quanti-
tative RT-PCR array and biochemical analysis show that, upon the
engagement of the TNF receptor with TNF-α on ECs, CD31 becomes
activated and, in turn, counteracts the proapoptotic transcriptional
program induced by TNF-α via activation of the Erk/Akt pathway.
Specifically, Akt activation by CD31 signals prevents the localization
of the forkhead transcription factor FoxO3 to the nucleus, thus
inhibiting transcription of the proapoptotic genes CD95/Fas and
caspase 7 and de-repressing the expression of the antiapoptotic
gene cFlar. Both CD31 intracellular immunoreceptor tyrosine-
based inhibition motifs are required for its prosurvival function.
In vivo, CD31 gene transfer is sufficient to recapitulate the cyto-
protective mechanisms in CD31− pancreatic β cells, which become
resistant to immune-mediated rejection when grafted in fully
allogeneic recipients.
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Maintenance of vascular integrity during inflammation is amajor challenge in the cooperation between the immune
and the vascular systems.
During acute inflammation, for example in solid organ trans-
plantation, endothelial cells (ECs) can themselves become targets
of innate and adaptive cytotoxic mechanisms, such as cytokines
including TNF-α, and cytotoxic T lymphocytes (CTLs). However,
with the exception of preformed antibody-triggered, complement-
mediated responses in hyperacute responses, damage of the en-
dothelium is relatively limited compared with that of other epi-
thelial components, and the vasculopathy occurring during chronic
rejection features abnormal perivascular responses leading to
endothelial dysfunction rather than direct loss of ECs (1). How
vascular integrity is maintained during inflammation has been the
subject of intense investigation (2–4).
Two major apoptosis pathways, namely the intrinsic and extrinsic
pathways, exist in mammalian cells (5). The first occurs under
conditions of cellular stress (oxidative injury, irradiation, exposure
to cytotoxic agents) via signals originating from the mitochondria.
The second is activated when TNF-family proteins such as TNF-α
and Fas ligand bind to TNF-family death receptors (DRs) on the
cell surface or during T-cell–mediated cytolysis.
Although ECs express DRs on their surface, TNF-α and Fas
ligand do not activate the extrinsic pathway of apoptosis in ECs
efficiently (6). The molecular mechanisms underlying this effect
remain elusive. Inhibition of the NFκB-dependent A1 or Bcl-xL
prosurvival genes does not sensitize ECs to TNF-α–induced
apoptosis, indicating that NFκB activation is not required for EC
protection (7). In contrast, EC survival upon exposure to TNF-α
or Fas ligand correlated with PI3K/Akt activation in a number of
studies (8, 9). Human EC resistance to TNF-α– and LPS-induced
apoptosis is dependent on new protein or mRNA synthesis, sug-
gesting that an inducible or constitutively expressed endothelial
protein is responsible for protection (10).
CD31, or platelet endothelial cell adhesion molecule-1, is a
member of the Ig gene superfamily expressed at high density at the
lateral borders of ECs and at a lower density on the surface of
hematopoietic cells (11). By establishing homophilic interactions
between endothelium- and leukocyte-expressed CD31, this mole-
cule has been shown to be involved in leukocyte transendothelial
migration in vitro and in vivo (11). CD31 signaling is mediated
mainly by two immunoreceptor tyrosine inhibitory motifs (ITIMs)
in its cytoplasmic tail (12). These ITIMs are phosphorylated upon
CD31 engagement and subsequently serve as docking sites
for protein-tyrosine phosphatases including the Src homology
2 domain-containing protein, SHP-2 (13).
CD31-deficient mice exhibit a very mild phenotype in steady-
state conditions (14). However, these animals display exaggerated
disease severity in inducible experimental models of T-cell–medi-
ated inflammation, including experimental autoimmune encepha-
lomyelitis (15), collagen-induced arthritis (16), atherosclerosis (17),
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and endotoxemia (18, 19), suggesting that CD31 signals play a
protective role under conditions of immunological stress.
The involvement of CD31 signaling in EC protection from the
intrinsic pathway of apoptosis, mostly in the context of exposure
to toxic drugs, has been described previously (20, 21).
In contrast, despite the large body of evidence pointing to an
endothelial-specific antiapoptotic pathway operational during
immune-mediated cell death (18, 19), a potential role for CD31
in protecting ECs from inflammatory insults inducing the ex-
trinsic pathway of apoptosis has not been investigated.
Results
CD31 Interactions Are Required for EC Protection from TNF-α– and
CTL-Induced Cell Death. To investigate a potential role for CD31 in
protecting ECs from the extrinsic pathway of apoptosis, we first
compared the susceptibility of WT or CD31-deficient murine pri-
mary microvascular ECs to apoptosis induced by canonical cell-
extrinsic apoptosis-inducing stimuli such as TNF-α and antigen-
specific CTLs or necrosis induced by the complement.
As shown in Fig. 1 A and B, CD31-KO ECs exposed to TNF-α
underwent a significantly higher rate of apoptosis than WT ECs.
Importantly, antibody blockade of CD31 activation (Fig. S1)
increased the rate of TNF-α–induced apoptosis in subcon-
fluent ECs (Fig. 1C), confirming that CD31 homophilic interac-
tions between ECs are necessary to confer resistance to TNF-
α–induced apoptosis.
We subsequently assessed the protective effect of CD31 ex-
pression by the endothelium from T-cell–mediated cytotoxicity.
Lymphocyte-mediated cytotoxicity can be induced both by
caspase-dependent apoptosis and by osmotic imbalance medi-
ated by perforin leading to necrosis (22). EC death induced by
CTLs therefore was measured by both TUNEL assay (selectively
measuring apoptosis) and by Trypan Blue (TpB) exclusion
(measuring overall cytolysis) in the same coculture. As shown in
Fig. 1 D and E, HY-specific CTL-mediated killing was significantly
increased in CD31-deficient male-derived ECs, indicating that
CD31 expression can protect ECs from CTL-mediated cytolysis, in
line with our previous observations with CD31-expressing antigen-
presenting cells (23). In addition, overall cell death, as measured
by TpB exclusion, was not quantitatively different from apo-
ptosis, as measured by TUNEL, suggesting that the latter
mechanism is dominant in CTL-mediated killing of ECs.
To establish whether CD31-mediated cytoprotection extended
to mechanisms of cell death other than apoptosis, a comparison
experiment was conducted on confluent murine ECs challenged
with xenogeneic human serum as a source of complement-fixing
antibodies (xenospecific IgM) and complement for 6 h. Because
complement-induced cytolysis is largely independent of caspase
activation, EC survival was assessed by TpB exclusion analysis,
revealing similar levels of cell death in WT and CD31-KO ECs
(Fig. 1F).
CD31 Is Required for the Activation of Erk/Akt Pathways Involved in
EC Cytoprotection from Extrinsic Apoptosis. To investigate the
molecular pathways involved in CD31-mediated EC survival upon
extrinsic proapoptotic stimuli, we assessed whether CD31 is in-
duced to signal upon TNF receptor (TNFR) engagement. EC ex-
posure to TNF-α promoted an increase in CD31 phosphorylation
and recruitment of the SHP-2 phosphatase to CD31-containing
complexes, indicating that TNFR signaling activates CD31 (Fig. 2A).
We recently have shown that in T cells CD31-mediated pro-
tection from activation-induced cell death, which is largely Fas-
dependent, is associated with Erk 1 and 2 but not NFκB acti-
vation (23). We therefore sought to assess whether the Erk/Akt
pathway was induced in our system. We found low constitutive
levels of Erk activation in WT and CD31-deficient ECs; these
levels increased significantly in WT but not in CD31-deficient
endothelium upon TNF-α stimulation (Fig. 2 B and C), suggesting
that in ECs CD31 engagement is required for Erk activation
downstream of TNFR signaling. Akt activation was induced fol-
lowing exposure of ECs to TNF-α in WT but not CD31-KO en-
dothelium (Fig. 2 B and D). The key role of these mediators in
protecting ECs from cell-extrinsic apoptosis was confirmed by
experiments in which ECs were incubated with TNF-α follow-
ing preincubation with selective Akt and ERK inhibitors; this
incubation led to significantly increased apoptosis (Fig. 2E).
Finally, Akt activation was reduced by blockade of CD31 antibody
in WT ECs (Fig. 2F).
CD31 Promotes a Prosurvival Transcriptional Program Downstream of
TNF-α Signals in ECs. Programmed cell death has been shown to be
regulated by a coordinated transcriptional program in which the
quantitative balance of pro- and antiapoptotic gene transcription
can determine the ultimate outcome of inflammatory stimuli (5).
Fig. 1. CD31 protects from extrinsic apoptosis. (A and B) WT and CD31-KO ECs were exposed to TNF-α (50 ng/mL) for 6 h, and apoptosis was measured by TUNEL
assay. (C) Alternatively, WT ECs were pretreated with either a blocking anti-CD31 or an isotype control antibody before exposure to TNF-α. (D and E) Male-derived
murine ECs (pretreated with IFN-γ for 48 h to up-regulate MHC molecule expression) were incubated for 6 h with HY-specific CTLs (EC:CTL ratio 1:5), which were
removed at the end of the incubation by gentle washing with warm PBS. EC death was measured by TUNEL assay and TpB exclusion assay. (F) ECs also were
cultured in 10% (vol/vol) human serum as a source of antibody and complement, and cell death was measured by TpB exclusion assay. Representative images are
shown in A and D. (Scale bars: 100 μm.) The mean percentages of apoptotic (B, C, and E) and necrotic (F) cells in three independent experiments (±SD) are shown.
***P < 0.001, ****P < 0.0001. NT, not treated.
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To identify downstream mediators of the CD31 survival ac-
tivity, we profiled the expression of apoptosis-related genes by
WT and CD31-deficient ECs following exposure to TNF-α by
using the RT2 profiler apoptosis array as described in Methods.
The mRNA expression levels were normalized to untreated
control cells.
Among the 84 genes analyzed, 19 were differentially regulated
in either WT or CD31-KO ECs upon TNF-α stimulation (three
uniquely in WT ECs, six uniquely in CD31-KO ECs, and 10 in both
WT and CD31-KO ECs), but no significant differences in gene
expression were observed when comparing resting WT (Dataset S1)
and CD31-KO (Dataset S2) ECs (Fig. S2).
Based on pairwise comparisons of TNF-α–treated WT and
CD31-KO ECs, the TNF-family DR CD95/Fas, the executioner
Caspase family member caspase 7, and the antiapoptotic gene
cFlar [CASP8 and Fas-associated protein with death domain
(FADD)-like apoptosis regulator, also designated as cFLIP (Flice-
like inhibitory protein)], were identified as genes that are tran-
scriptionally repressed (Fas, caspase 7) or are transcribed de novo
(cFlar) in WT but not in CD31-KO ECs in response to TNF-α.
The differential regulation of Fas and caspase 7 at the
mRNA level was confirmed further by quantitative real-time
PCR (qRT-PCR) Fig. 3 A and D) and at the protein and
functional levels (Fig. 3 B, C, and E) by measuring Fas ex-
pression and caspase 7 activity by TNF-α–stimulated WT and
CD31-deficient ECs via the use of flow cytometry and the
Caspase 3/7 Assay. Because caspase 3 and 7 are shared by the
intrinsic and extrinsic apoptosis pathways (5), inhibition of the
latter by CD31 signals was confirmed by measuring caspase 8
activity (Fig. 3F).
We also compared the expression of programmed death ligand
1 (PDL-1), a negative costimulator of T cells not included in the
RT2 profiler that is known to be expressed by the endothelium
(4), and observed no differences between WT and CD31-deficient
ECs (Fig. S3A).
We further observed that ECs express the serine protease in-
hibitor 6 (serpin B9/Spi6), known to provide protection from
granzyme-induced cytotoxicity (22), and that Spi6 transcription
was induced by exposure to TNF-α; however this transcription
occurred independently of CD31 expression (Fig. S3B). Finally,
we did not observe significant differences in reactive oxygen
species (ROS) production by TNF-α–stimulated WT and CD31-
deficient ECs (Fig. S3C), suggesting that CD31-mediated pro-
tection does not depend on the induction of antioxidant activity.
Fig. 2. Antiapoptotic pathways activated by CD31 in ECs. (A) Immunoprecipitation of CD31 molecules from ECs exposed to TNF-α for 20 min followed by
immunoblotting with an anti-phosphotyrosine antibody and an anti-SHP2 antibody. (B–D) Erk (B and C) and Akt (B and D) activation in WT and CD31-KO ECs
exposed to TNF-α; time points are indicated. (E) WT ECs were treated with an Akt inhibitor (3 μM) or with a MEK 1/2 inhibitor (10 μM) for 4 h at 37 °C before
incubation with TNF-α. EC apoptosis was measured after 6 h by TUNEL assay. (F) Akt activation in WT ECs pretreated with a blocking anti-CD31 or an isotype
control antibody and exposed to TNF-α for 30 min. In C–E the mean percentage of apoptotic cells in three independent experiments (±SD) is shown. *P < 0.05,
**P < 0.01, ***P < 0.001.
Fig. 3. CD31 modulates the proapoptotic transcriptional program downstream of DR signaling. (A–C) Expression of Fas mRNA and surface receptor by WT
and CD31-KO ECs either untreated or exposed to TNF-α for 6 h as quantified by qRT-PCR (A) and flow cytometry (B and C). (D–F) Expression of caspase 7 mRNA
and caspase 3/7 and caspase 8 activity by WT and CD31-KO ECs, either untreated or exposed to TNF-α as measured by qRT-PCR (D), ApoTox-Glo Triplex Caspase
3/7 (E), or Caspase 8 Reagent (F). In A and C–F cumulative data from three independent experiments (±SD) are shown. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001. MFI, mean fluorescence intensity.
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cFlar is an antiapoptotic protein with significant homology to
caspase 8 (24). By competitively binding to FADD and blocking
the assembly of a functional death-inducing signaling complex
(DISC), cFlar inhibits the activation of upstream initiator caspases,
including caspase 8 (25). cFlar previously has been shown to be
induced downstream of Akt and to be required for EC protection
from LPS-induced apoptosis (10) as well as Fas-induced cell death
(7). We therefore further investigated the involvement of this gene
in the cytoprotective effect of CD31. qRT-PCR and immunoblot-
ting experiments confirmed the lack of cFlar gene transcription and
protein synthesis in CD31-KO ECs upon TNF-α stimulus (Fig. 4 A
and B). cFlar knockdown by shRNA in WT ECs (Fig. 4 C and D)
enhanced their sensitivity to TNF-α–induced apoptosis, and this
enhanced sensitivity could not be rescued by CD31 antibody
stimulation (Fig. 4E) (23).
Importantly, inhibition of Akt and Erk activation prevented
cFlar expression by WT ECs exposed to TNF-α (Fig. 4F), sug-
gesting that these pathways, which require CD31 expression for
activation downstream of TNFR signaling (Fig. 2 B–F), directly
mediate the induction of cFlar transcription.
We next asked how Akt induces cFlar expression downstream
of CD31 signals. Akt activation is known to be antiapoptotic by
multiple mechanisms. One of the best described is the phosphory-
lation of forkhead box O (FoxO) transcription factors, driving these
proteins from the nucleus, where they induce the transcription of
proapoptotic molecules and inhibit transcription of antiapoptotic
ones (26). Of relevance here, FoxO proteins are known to inhibit
cFlar transcription (27, 28). We therefore analyzed the distribution
FoxO3 in WT and CD31-deficient ECs following exposure to
TNF-α. As shown in Fig. 4 G and H, FoxO3 proteins were
prevented from localizing in the nucleus in WT but not CD31-KO
ECs upon TNF-α stimulation. Thus it is likely that CD31 signals
block TNF-α–induced proapoptotic gene reprogramming by pre-
venting nuclear localization of FoxO3 protein via activation of Akt.
Both Intracellular ITIMs Are Required for CD31 Antiapoptotic Activity.
Both ITIM-mediated signals and homophilic binding have been
shown previously to be required for efficient CD31 protection
from the intrinsic apoptotic pathway (20). To investigate whether
these signaling domains also are required for CD31-mediated in-
hibition of the extrinsic pathway, we generated two CD31 gene
constructs with mutations leading to the loss-of-function amino acid
substitutions Y663F and Y686F in the ITIMs, which were lenti-
virally transduced into CD31-KO ECs (CD31Y663F and CD31Y686F
ECs). As shown in Fig. 5, both CD31Y663F and CD31Y686F mutant
receptors fail to protect ECs (Fig. 5A) from TN-Fα– and CTL-
mediated apoptosis (Fig. 5 B–D) and exhibited impaired Erk and
Akt activation compared with CD31 WT ECs (Fig. 5 E–G). Fur-
thermore neither mutant was able to suppress TNF-α–induced ex-
pression of CD95/Fas (Fig. 5 H and I) or the transcription and
activity of caspase 7 and 8 (Fig. 5 J–L), or promote the expression of
cFlar (Fig. 5M), and both failed to prevent the localization of FoxO
protein to the nucleus upon exposure to TNF-α (Fig. 5 N and O).
As expected, expression of Spi6 was not affected in CD31Y663F
and CD31Y686F ECs (Fig. S4). Overall these data suggest that both
CD31 ITIMs are required for CD31-mediated EC cytoprotection.
CD31 Expression Confers Resistance to Cytolysis by Alloreactive T Cells
and Promotes Graft Survival. We next sought to establish whether
CD31’s antiapoptotic activity is both necessary and sufficient to
maintain EC survival during activation of the extrinsic pathway of
apoptosis in physiologic immune responses.
Rejection of HY-mismatched skin grafts is dependent on anti-
gen presentation by the endothelium (29), and skin is a major
target of graft-versus-host disease (GVHD), which is affected by
CD31 polymorphism in humans (30). Therefore, we first com-
pared rejection of male-derived WT and CD31-KO skin grafts by
syngeneic female recipients. Analysis of the vascular endothelium
at day 7 after transplantation revealed the maintenance of the
Fig. 4. The antiapoptotic gene cFlar is instrumental to CD31-mediated cytoprotection. mRNA was isolated from CD31-KO or WT ECs either untreated or
stimulated with TNF-α (50 ng/mL) for 6 h. (A and B) cFlar mRNA quantification (A) and protein expression (B) by WT and CD31-KO ECs after incubation with
TNF-α. (C and D) cFlar expression by ECs following shRNA knockdown was evaluated by qRT-PCR (C) and immunoblotting (D). (E) Apoptosis of ECs exposed to
TNF-α following cFlar knockdown measured by TUNEL assay. In some cFlar-silenced cells, CD31 was stimulated by antibody ligation. pLKO.1 indicates cells
transduced with the empty vector backbone. (F) WT ECs were treated with an Akt inhibitor (3 μM) or a MEK1/2 inhibitor (10 μM) before incubation with TNF-α.
Expression of cFlar was measured after 6 h. (G and H) EC cultures were fixed, and FoxO3a intracellular localization was assessed by immunofluorescence staining.
Nuclei were stainedwith DAPI. Representative images are shown inG. (Scale bars: 50 μm.)H shows the quantification of immunofluorescence staining patterns for
endogenous FOXO3 (n = 100 cells per experiment). The data shown in A, C, E, and H are the mean value (±SD) of three independent experiments. **P < 0.01,
***P < 0.001, ****P < 0.0001.
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donor vasculature within the graft (Fig. S5 A–D) and the estab-
lishment of direct anastomosis of the donor’s and recipient’s
vasculature (Fig. S5E), indicating that this model is suitable for
assessing vascular rejection. As shown in Fig. 6A, the survival of
CD31-deficient skin grafts was reduced significantly compared with
that of WT skin. As expected, both CD31-KO and WT female-
derived control grafts survived indefinitely. Male-derived WT skin
grafts excised at day 14 after transplantation displayed relatively
moderate mononuclear cell infiltration with preservation of hair
follicles and vessels in the dermis on histological examination (Fig.
6 B and C). CD31-deficient male-derived skin grafts displayed
thinning of the epidermis accompanied by extensive necrosis of
dermis tissue and hair follicles and, importantly, EC damage and
loss in small vessels (Fig. 6 D and E) despite similar mononuclear
cell infiltrates. All these features are indicative of overwhelming
vascular damage. However, to rule out the possibility that CD31-
deficient dendritic cells of graft origin might have enhanced the
proliferation of HY-specific CTLs, we quantified HY-specific CD8+
T cells in the graft-draining lymph nodes 7 d after transplantation
(i.e., at the peak of T-cell expansion) by Uty tetramer staining. We
did not detect any differences in the number of HY-specific T cells
rejecting WT or CD31-KO male skin grafts (Fig. 6 F and G).
To confirm the nonredundant protective role of CD31 in allo-
graft rejection, we tested whether transfer of CD31 expression
would endow cells that do not physiologically express this molecule
with resistance to extrinsic apoptosis. CD31−, H2b-expressing
MIN6 (28) pancreatic β cells were transduced with the WT CD31
gene or were mock-transduced with the empty vector (Fig. 7A).
The efficiency of gene transfer (shown in Fig. 7A) did not affect
insulin production in response to glucose stimulation in nontreated
Fig. 5. Both CD31 ITIMs are required for its prosurvival activity. CD31 gene constructs with mutations leading to the loss-of-function amino acid substitutions
Y663F and Y686F in the ITIMs were generated and expressed by lentiviral transduction into CD31-KO ECs (CD31Y663F and CD31Y686F). As a control, CD31-KO ECs
were transduced with aWT CD31 gene construct or an empty plasmid (mock). (A) Surface expression of CD31Y663F and CD31Y686F molecules following transduction
of CD31-KO ECs. As a control, WT CD31 and empty plasmid (mock) constructs were used. (B and C) Apoptosis of mock-, WT-, CD31Y663F-, and CD31Y686F-transduced
CD31-KO ECs either exposed to TNF-α for 6 h or cocultured with antigen-specific CTLs for 6 h, as measured by TUNEL assay. (D) Complement-mediated lysis of the
indicated EC populations. (E–G) Erk and Akt activation in ECs transduced with the indicated constructs following exposure to TNF-α. (H–M) CD95/Fas surface
expression (H and I), caspase 7 expression and activity (J and K), caspase 8 activity (L), and cFlar protein expression (M) in the indicated EC populations,
either untreated or exposed to TNF-α for 6 h. In B–D, F, G, and I–L the mean value of data measured in three independent experiments (±SD) is shown. **P < 0.01,
***P < 0.001, ****P < 0.0001. (N and O) Mock-, WT-, CD31Y663F- and CD31Y686F-transduced ECs were fixed, and FoxO3a intracellular localization was assessed by
immunofluorescence staining. (N) Nuclei were stained with DAPI, and representative images were taken by deconvolution wide-field immunofluorescence mi-
croscopy. (Scale bars: 50 μm.) (O) Quantification of immunofluorescence staining patterns for endogenous FoxO3 (n = 100 cells per experiment). Data represent
the mean value (±SD) of three independent experiments. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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cells (Fig. 7B). Transduction of the CD31 gene in MIN6 cells
fully recapitulated the cytoprotective effects observed in ECs,
including maintenance of insulin production (Fig. 7B) and re-
sistance to TNF-α–induced cell death (Fig. 7 C and D) and CTL-
mediated cytolysis (Fig. 7 E and F). Interestingly, the protective
effect of CD31 on CTL-mediated lysis of pancreatic β cells was not
as complete in MIN6 cells as in ECs (Fig. 1 D and E). MIN6 cell
killing was prevented completely only by the inhibition of both DR
signaling and lytic granule release (Fig. 7G), indicating that per-
forin-induced osmotic lysis is only partially inhibited by CD31
signals. FoxO3, which has been implicated in osmotic lysis (31),
localized to the nucleus only in mock-transduced but not in CD31-
expressing MIN6 cells after incubation with CTLs (Fig. 7H).
Similar to our observations in ECs (Fig. 1C), antibody blockade
of CD31 in transduced MIN6 cells significantly increased their sus-
ceptibility to CTL-induced death (as measured by TpB) to the levels
observed when mock-transduced cells were used as targets (Fig. 7I).
The acquired resistance of MIN6 cells to TNF-α and CTL-
induced death was associated with activation of the Erk/Akt
pathway (Fig. 8A), down-regulation of Fas (Fig. 8B), caspase 7
expression and activity (Fig. 8 C andD), caspase 8 activity (Fig. 8E),
up-regulation of cFlar expression (Fig. 8F), and inhibition of FoxO3
nuclear localization (Fig. 8G).
Like ECs, MIN6 cells were found to express the Spi6 gene and
up-regulate its transcription upon TNF-α stimulation (Fig. S6).
However, transduction of CD31 did not modify its expression
and indeed resulted in a lower level of up-regulation following
exposure to TNF-α, suggesting that this molecule is not impli-
cated in the acquired resistance to perforin-mediated apoptosis
by CD31-expressing MIN6 cells.
Collectively, these data suggest that expression of CD31 con-
fers cytoprotection to MIN6 cells by mechanisms very similar to
those observed in ECs.
To establish whether CD31 expression is sufficient to prevent
the induction of cell-extrinsic apoptosis, as in CTL-mediated
allograft rejection, in physiologic settings, we chose to assess
rejection of CD31-expressing pancreatic β cells grafted in a fully
allogeneic recipient.
Mock- or CD31-transduced MIN6 cells were grafted under the
renal capsule of BALB/c mice that had been rendered diabetic
by injection of streptozotocin (STZ) 3 wk earlier. As a control,
WT MIN6 cells were grafted in syngeneic C57BL/6 diabetic
mice, leading to complete normalization of glycemia (Fig. 9A).
As shown in Fig. 9B, diabetes persisted in recipients of WT
MIN6 cells, indicating transplant rejection. In contrast, in re-
cipients of CD31-expressing MIN6 cells glycemia returned to
normal for the duration of the experiment. Healthy CD31-
expressing MIN6 islets were detected in the kidney of these
recipients, suggesting that these cells had become resistant to re-
jection (Fig. 9 C and D).
An analysis of anti–H-2D alloresponses revealed that these
responses were conserved both in animals that received WT and
those that received CD31-expressing MIN6 cells (Fig. 9E), sug-
gesting that CD31 transduction led to the induction of immune
privilege rather than tolerance.
Discussion
We report here that the Ig-family receptor CD31, which is se-
lectively expressed by ECs at high density, becomes activated
upon the delivery of proapoptotic immune stimuli and is both
necessary and sufficient to prevent EC death as a consequence of
these signals. Importantly, we show that the apoptotic stimuli
themselves induce CD31 activation, which in turn counteracts
the proapoptotic gene reprogramming initiated by such stimuli.
Because EC cultures are nonconfluent, it is likely that CD31
signaling triggered by TNF-α is initiated by cis interactions of
CD31 molecules. This mechanism also is supported by the
observation that the anti-CD31 antibody, which has been
shown to prevent cis interactions by CD31 (32), inhibited
CD31-mediated prosurvival activity induced in response to TNF-α.
Activation of CD31 signaling by CTLs is likely to be induced by
distinct mechanisms: first, CTLs’ interaction with EC might lead to
Fig. 6. Enhanced rejection of CD31-deficient skin grafts. WT female mice received either a WT or CD31-KO male-derived skin graft. As a control, female WT and
CD31-KO female-derived skin was used. (A) Graft survival (n = 6). ****P < 0.0001. (B–D) In some recipients, WT or CD31-KO grafts were harvested 14 d after
transplantation. Representative tissue sections of grafts from femaleWT (B) and CD31-KO (D) controls andmaleWT (C) and CD31-KO (E) mice stained with H&E. 1,
epidermis; 2, mononuclear inflammatory cells; 3, hair follicles; 4, dermis vessels. (F and G) Allograft-draining lymph nodes were harvested 7 d posttransplantation,
and the presence of HY-specific CD8 T cells was evaluated by tetramer staining. (F) Representative dot-plots. (G) The mean percentage of CD8+ tetramer+ T cells
from six animals.
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trans-CD31 ligation (23). Alternatively, CD31 might be activated
indirectly by MHC ligation by the T-cell receptor (33).
Activated inflammatory cells, including the endothelium, un-
dergo active shedding of the extracellular domain of the CD31
molecule (34, 35); this shedding could contribute to the loss of
cell–cell adhesion (34) and to the rise in circulating soluble (s)CD31
during inflammatory diseases (35). Although a potential physi-
ologic role of sCD31 serum levels in vivo remains to be determined,
the membrane-anchored truncated protein remains capable of sig-
naling (35); hence, the loss of the CD31 extracellular domain should
not affect its ability to interfere with apoptosis.
Rather than interfering with proapoptotic signaling pathways di-
rectly, CD31 signals prevent ad hoc proapoptotic genetic reprog-
ramming by redirecting the transcription factor FoxO3 to the
cytoplasm via Akt-mediated phosphorylation (Fig. S7). This is a
previously unknown pathway for the acquisition of immune privilege.
Tissue immune privilege, originally thought a consequence of
the inability of immune cells to access target tissue, is currently
viewed as the ability of the tissue itself to downmodulate T-cell
effector function during cognate recognition of self- and allo-
antigens (36). For example, expression of Fas ligand by cells in
the anterior chamber of the eye and by the Sertoli cells in the
testis preserves their integrity against immune attack by inducing
death of CD95 (Fas)-expressing T lymphocytes (37, 38). Privi-
leged tissues also feature other protective mechanisms, such as a
tight endothelial barrier, down-regulation of MHC molecules,
and production of anti-inflammatory cytokines such as TGF-β.
The term “immune privilege” also implies that the protective
mechanism(s) apply only to selective cellular components (36).
A plethora of signals have been proposed to sustain EC survival
in vivo, including adhesion to the basement membrane and to
adjacent ECs, growth factors, and survival signals derived from
pericytes (6). However, most of these signals selectively prevent
mitochondrial apoptosis. In addition, a number of mechanisms have
been identified that modulate EC activation or deliver inhibitory
signals to cytotoxic T cells; for example, the Down syndrome critical
region gene 1, which is induced by inflammatory mediators, reduces
the expression of ICAM-1, VCAM, and E-selectin by ECs (2). ECs
also can regulate CTL responses negatively by expressing coinhi-
bitory receptors such as Herpes simplex entry mediator (3) and
programmed cell death ligand-1 (4). However, these mechanisms
also apply to cells of nonendothelial lineage, which nevertheless are
susceptible to immune-mediated damage.
Our study indicates that CD31, which is expressed specifically at
high levels by ECs, selectively endows the vascular endothelium
with the ability to maintain vascular integrity actively during im-
mune inflammation and as such behave like an immune-privileged
tissue. Our observations further suggest that, in response to ex-
trinsic apoptotic stimuli, CD31 engages a prosurvival pathway
that is distinct from that induced by intrinsic stimuli (20), with
Fig. 7. CD31-transduced pancreatic β cells are protected from extrinsic apo-
ptosis. (A) Surface expression of CD31 by mock- and CD31-transfected MIN6
cells. (B) Insulin secretion by untreated and TNF-α–exposed mock- and CD31-
transfected starved MIN6 cells incubated in DMEM containing 2.8 mM glucose
for 30 min at 37 °C, measured 1 h after reconstitution with 25 mM glucose.
(C–F) Cell death of mock- and CD31-transfected MIN6 cells either exposed to
50 ng/mL TNF-α for 6 h (C and D) or cocultured with allospecific CTLs for 6 h (E
and F) as measured by TUNEL and TpB assays. Representative images are
shown in C and E. (Scale bars: 100 μm.) (G) Apoptosis of mock- and CD31-
transfected MIN6 cells cultured with allospecific CTLs for 6 h and pretreated
with a DR ligand (DRL) inhibitor (5 μM) and/or concanamycin A (5 μg/mL) for 1 h.
(H) FoxO3a intracellular localization in MIN6 cells was assessed by immunofluo-
rescence staining following coculture with CTLs (MIN6:CTL ratio 1:5) for 6
h. Quantification of immunofluorescence staining patterns for endoge-
nous FOXO3 is shown (n = 100 cells per experiment). (I) Apoptosis of CD31-
transfected MIN6 cells cultured with CTLs for 6 h following treatment with
a blocking anti-CD31 antibody or isotype control. Mock-transduced cells
are included for comparison. Data in B, D, and F–I are the mean percent-
age (±SD) of apoptotic cells measured in three independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 8. Antiapoptotic pathways activated in CD31-transduced pancreatic β
cells. (A–F) Erk and Akt activation (A), Fas surface expression (B), caspase 7
expression and activity (C and D), caspase 8 activity (E), and cFlar protein
expression (F) by mock- and CD31-transfected MIN6 cells exposed to TNF-α
for 6 h. (G) Nuclear localization of FoxO3 in MIN6 cells exposed to TNF-α for
6 h. Quantification of immunofluorescence staining patterns for endoge-
nous FOXO3 is shown (n = 100 cells per experiment). Data in C–E and G are
the mean value (±SD) of three independent experiments. **P < 0.01.
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the Akt/Erk pathway being dominant during extrinsically in-
duced apoptosis.
Interestingly, cellular resistance to immune-mediated cell death
correlates strictly with CD31 expression in some cells of hemato-
poietic origin. We previously have reported that CD31 reduces
cytotoxic killing of antigen-presenting cells (23). Selective expres-
sion of CD31 by endothelium and dendritic cells may serve the
purpose of preserving their integrity and function during immune
inflammation; thus, the endothelium can mediate the development
of inflammatory infiltrates without being damaged by migrating
activated leukocytes, and antigen-presenting dendritic cells can
serially activate multiple cognate T cells without themselves being
killed at the first encounter. Intriguingly, aberrant expression
of CD31 has been described in some tumors and correlates
with adverse prognosis (21), leading to the hypothesis that CD31
expression by nonendothelial tumors may facilitate metastasis via its
ability to bind homophilically to endothelial CD31 and/or by con-
ferring resistance to chemo- and radiotherapy (21). Based on our
observations, prosurvival signals generated by CD31 interactions also
might be harnessed by tumors to become resistant to immune attack.
In support of a physiologic role of CD31 in protecting the en-
dothelium from immune-mediated damage, we show that loss of
CD31 expression by skin allografts leads to accelerated rejection
featuring extensive vascular damage and necrosis rather than
overwhelming T-cell activation and inflammation. In line with our
findings, enhanced endothelial loss was prominent during the re-
jection of CD31-deficient aortic transplants (17).
Finally, we show that CD31 gene transfer is sufficient to re-
capitulate the cytoprotective mechanisms in CD31− pancreatic β
cells, which become resistant to immune-mediated rejection when
grafted in fully allogeneic recipients. This finding is an un-
expected and previously unreported observation, with potential
therapeutic impact.
The ability of CD31 expression to protect MIN6 cells from
CTL-mediated killing appears to affect not only DR-induced
apoptosis but also perforin-mediated lysis, which does not play a
significant role in EC cytolysis. The molecular mechanism of this
effect is unclear at present, and it does not involve induction of
the Serpin inhibitor Spi6. Notably, IL-4–induced phosphoryla-
tion of another FoxO family member, FoxO1, has been shown to
prevent EC cytolysis by up-regulating claudin-5 expression and
junction tightness (31).
In addition to their relevance in basic vascular physiology, the
findings described here might have a broader impact on vascular
pathology. CD31 has been implicated in the development of ath-
erosclerosis and its clinical complications (39, 40). A few studies have
described a link between the development of human atherosclerosis
and the presence of CD31 SNPs. Interestingly, a number of the
CD31 SNPs that have been associated with atherosclerosis (41–44)
are the same as those implicated in increased GVHD severity (45–
49). The functional significance of these SNPs has yet to be explored,
and their association with disease remains controversial (50). How-
ever, it is interesting that the SNP at position 670 is located in
proximity to the cytoplasmic ITIMs, which, as we show, are key for
CD31 signal transduction and prosurvival activity.
Methods
Mice. CD31-KOmice were generated as previously described (14), backcrossed
on the C57BL/6 background, and bred in house. Age- and weight-matched
WT C57BL/6 mice were purchased from Charles River. All mice in this study
were used between the ages of 4 and 11 wk. All in vivo experiments were
conducted under the Home Office regulation following approval by the
Queen Mary University of London Ethics Committee.
Reagents and Antibodies. The reagents used in this study include recombinant
murine TNF-α (PeproTech), AKT inhibitor (Akt Inhibitor X; Calbiochem), and
ERK inhibitor (PD98059; Cell Signaling). The vacuolar type H+-ATPase in-
hibitor concanamycin A, which completely blocks perforin-based cytotoxic
activity by T lymphocytes, was purchased from Santa Cruz Biotechnology.
The DR inhibitor CAS 1049741-03-8 was purchased from Merck Millipore.
The antibodies used in this study include anti–P-Akt (ser-473) (1:1,000), anti-
Akt (1:1,000), anti–P-ERK1/2 (1:1,000), anti-ERK1/2 (1:1,000; Cell Signaling),
anti–P-tyrosine (PY20; 1:500), anti-SHP2 (1:500; Abcam); anti–FLIP-L (1:500),
and anti–α-actin (1:1,000; Santa Cruz Biotechnology). For staining of the
endothelium in skin grafts and EC cultures, rat anti-mouse CD31 antibody
(102501; BioLegend) and sheep anti-mouse von Willebrand factor (VWF)
(ab11713; Abcam) and secondary antibodies Alexa Fluor 488 donkey anti-
sheep IgG (H+L) (A-11015; Life Technologies) and Alexa Fluor 594 donkey
anti-rat IgG (H+L) (A-21209; Life Technologies) were used. For flow cytom-
etry staining rat anti-mouse CD31 antibody clone 390 (eBioscience) was
used. The IgG2a, kappa, and Rat IgG2a K Isotype Control Purified (clone
eBR2a) were purchased from eBioscience. As a blocking reagent (Fig. S1), rat
Fig. 9. CD31-expressing pancreatic β cells become resistant to T-cell–medi-
ated allograft rejection. (A and B) The function of mock-transduced and
CD31 MIN6 islets was evaluated by measuring blood glucose levels in grafted
syngeneic (C57BL/6) (A) or allogeneic (Balb/C) (B) mice rendered diabetic by
STZ injection. (C and D, Left) Representative images of a kidney that received
either mock- or CD31-transduced MIN6 β cells and was stained to detect
insulin production. (Right) Magnified sections of the grafts processed as in-
dicated. (Scale bars: 100 μm.) (E) At the time mice were killed, T cells were
isolated from the spleen and lymph nodes of recipients and labeled with
carboxyfluorescein succinimidyl ester (CFSE). Cell division in response to an
ex vivo rechallenge with C57BL/6 splenocytes by T cells from naive mice
(recipients of mock-transduced or CD31 MIN6 cells) was measured by flow
cytometry. Representative histograms show percent division, division indices,
and proliferation indices as determined by FlowJo. **P < 0.01, ***P < 0.001.
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anti-mouse CD31 Antibody clone 390 (eBioscience) was used at a concen-
tration of 10 μg/mL. To stimulate signaling, CD31 molecules were ligated
with polyclonal rabbit anti-mouse CD31 (5 μg/mL) (ab28364; Abcam) plus
goat–anti-rabbit Ig (2.5 μg/mL) (Thermo Scientific). For the detection of
HY-specific T cells, phycoerythrin (PE)-conjugated Db-Uty Tetramer (pep-
tide WMHHNMDLI; Medical and Biological Laboratories Co. Ltd.) and FITC-
conjugated rat anti-mouse CD8 (11-0081-85; eBioscience) were used.
Cell Cultures. Murine ECs were purified from WT and CD31−/− mouse lung
tissue as described previously (51). ECs were serially subcultured at 37 °C with
5% CO2 in DMEM supplemented with 2 mM glutamine, 100 μg/mL penicillin,
100 μg/mL streptomycin, 1 mM sodium pyruvate, 10 mMHepes, 1% nonessential
amino acids (all from Life Technologies), and 50 μM 2-mercaptoethanol (Sigma-
Aldrich), with freshly added 20% (vol/vol) heat-inactivated FCS (Labtech
International) and 75 μg/mL EC growth supplement (Sigma-Aldrich) in 2% (vol/
vol) gelatin-coated (Sigma-Aldrich) tissue-culture flasks. At confluence, ECs were
detached from the culture flasks using trypsin/EDTA (Life Technologies) and
were passaged. In all experiments, ECs were used between passages 3 and 4.
CD8+ HY (male)-specific H2-Db–restricted CTLs were generated by stimu-
lation of T cells isolated from the lymph nodes of C57BL/6 female mice with
splenocytes isolated from syngeneic male mice and IL-2 (20 U/mL; Roche) for
10 d in RPMI medium 1640 supplemented with 10% (vol/vol) FCS (Labtech
International), 2 mM glutamine, 50 μg /mL penicillin, 50 μg/mL strepto-
mycin, and 50 μM 2-mercaptoethanol (all from Life Technologies). CD8+ T
cells were subsequently isolated by immunomagnetic negative selection
(Miltenyi Biotech) before use.
In cytotoxicity assays T cells were incubated with IFN-γ–treated ECs derived
from WT and CD31-deficient female mice (H-2b background) pulsed with the
HY-derived Uty peptide (52). As a control non–peptide-pulsed ECs were used.
MIN6 cells (SV40 T-transformed pancreatic β cells derived from NOD mice)
were grown in DMEM culture medium containing 25 mM glucose (Life
Technologies) supplemented with 15% (vol/vol) FBS, 2 mM glutamine, 100
μg/mL penicillin, and 100 μg/mL streptomycin.
Complement Lysis Assay. As a source of complement and complement-fixing
xenoantibodies, human serum was obtained after sedimentation of blood of
healthy donors (Queen Mary Ethics of Research Committee Ethical Approval
QMERC2014/61). Sterile tubes without any anticoagulants were used to
separate serum from the blood cells, and the tubes were left in a standing
position for about 20–30 min before centrifugation at 1,500 × g at 20 °C for
10 min. Serum then was extracted and frozen at −80 °C. In cell lysis assays,
the human serum was diluted 1:10 in RPMI medium and then was added to
murine EC monolayers, which were incubated at 37 °C.
Gene-Expression Analysis by qRT-PCR. Total RNA was extracted with TRIzol
(Life Technologies), purified using the PureLink RNA minikit (Life Technolo-
gies), and assessed for quality and quantity using absorption measurements.
RNA with an RNA integrity number of ≥7.6 was used for analysis of apoptosis
using pathway-focused RT-PCR array systems (RT2 Profiler PCR Array Mouse
Apoptosis; Qiagen) and an Applied Biosystems 7500 Fast Real-Time PCR ma-
chine (Life Technologies). Ct values were gathered using 7500 Fast System SDS
Software (Applied Biosystems). Comparative data analysis was performed via
the ΔΔCt method using the PCR Array Data analysis web portal (www.
sabiosciences.com/RTPCR.php) to determine relative expression differences
between the comparison groups. Changes of mRNA abundances by twofold and
higher with a P value <0.05 were considered significantly different between the
comparison groups as shown. Confirmation studies and relative quantification of
additional genes was performed using the QuantiFast SYBR Green RT-PCR Kit
(Qiagen) with 100 ng RNA per reaction and following the manufacturer’s pro-
tocol. Specific primers for qRT-PCR were designed with the help of online tools
(Primer 3Plus) using at least one exon junction-binding site per primer pair.
Sequences of the qRT-PCR primers are as follows:
CD95 (5′-ATGCTGGGCATCTGGACCCT-3′ and 5′-CAACATCAGATAAATTTA-
TTGCCAC-3′);
cFlar (5′-GACCCTTGTGCTTCCCTA-3′ and 5′-GTTAATCACATGGAACAATT-
TCC-3′);
Caspase 7 (5′-CTACCGCCGTGGGAACGATGGCAGA-3′ and 5′-CGAAGGCC-
CATACCTGTCACTTTATC-3′);
Spi6 (5′-CAGAGTTGTTGTCAGGTGGC-3′ and 5′-CGACACATCATCTGCAC-
TGG-3′);
GAPDH (5′-AGAACGGGAAGCTTGTCATCA-3′ and 5′-GACCTTGCCCACAGC-
CTTG-3′).
The thermal cycling profile for amplification was 95 °C for 10 min, followed
by 40 cycles of 95 °C for 15 s and 54 °C for 1 min. Amplification was 95 °C for
10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. To ensure
the amplification specificity, the melting curve program was set as follows:
95 °C for 15 s, 60 °C for 1 min, and 95 °C for 15 s, right after the PCR cycles.
FoxO3a Staining. EC cultures were fixed and stained with an anti–FKHRL-1
(EP1949Y) (1:50) (Abcam) and the secondary antibody Alexa-Fluor 555.
FoxO3a patterns of intracellular localization were quantified using specifi-
cally designed software to run in the LabView version 7.1 (National In-
struments) environment. This automatic cell-counting algorithm is based on
a combination of background subtraction, multiple thresholding, and mor-
phological processing approaches (53).
Caspase Activity Assays. For caspase 3/7 measurements, cells were seeded in
96-well plates and incubated with or without inflammatory stimulus. Then,
Caspase-Glo 3/7 or Caspase 8 Reagent (Promega) was added according to the
manufacturer’s protocol. The samples were incubated for 15 min in the dark
and then were analyzed. Luminescence intensity was measured with a
fluorometric imaging plate reader (BioTek Instruments).
Lentivirus Preparation for Gene Silencing and Overexpression. Bacterial glycerol
stocks containing shRNA plasmid clones targeting cFlar cloned in the pLKO.1
vector were purchased from Sigma. Lentivirus packaging and envelope vectors
pMDLg/pRRE, pRSV-Rev, and pENV were purchased from Addgene. cDNA of
murine CD31 fused in-framewith GFP at the C terminuswas used as template to
generate tyrosine-to-phenylalanine (Y-to-F) mutations at the amino acids res-
idues 663 and 686 (Y663F or Y686F, respectively) using the QuikChange site-
directed mutagenesis kit (Stratagene). WT, Y663F, and Y686F CD31 cDNAs were
subcloned into the pWPT lentiviral expression vector at MluI and SalI restriction
sites and were checked by sequencing. Lentivirus packaging and envelope
vectors R8.91 and MD2G were purchased from Addgene. HEK293T cells were
grown in 10 × 10 cm cell-culture dishes to 70% confluence and were trans-
fected with the plasmids listed above using the calcium phosphate method.
The supernatant was harvested 48 and 72 h after transfection and was con-
centrated 100-fold in an ultracentrifuge. Aliquots were stored at −80 °C.
Lentiviral Transduction of ECs and MIN6 Cells. CD31−/− ECs and MIN6 cells were
seeded in six-well plates and cultured in DMEM to 60–70% confluence. Lentivirus
was added to the cells in the presence of 5 μg/mL Polybrene (Sigma-Aldrich), and
the six-well plate was centrifuged at 2,300 rpm (Heraeus Multifuge X3R, rotor
Thermo Scientific 75003607) for 90 min at room temperature, followed by 8 h
incubation at 37 °C with 5% CO2. Virus was removed 24 h later; T cells were
washed twice with PBS and incubated for 24 h in complete DMEM. Expression of
GFP enabled tracking and sorting of infected cells by flow cytometry.
Skin Grafting. Skin grafting was performed using a method previously de-
scribed by Billingham and Medawar (54) using tail skin grafted onto the
lateral thorax. Briefly, donor tail skin was removed and cut into 1-cm2 sec-
tions. Recipient mice were anesthetized using isoflurane (Halocarbon Prod-
ucts Corp.). A piece of skin was removed from the right flank to create a
graft bed, and a 1-cm2 piece of tail skin was placed in the graft bed. The
graft was covered with muslin, and a plaster cast was wrapped around the
midriff and graft. Plasters were removed 7–10 d after grafting, and grafts
were inspected every other day.
Transplantation of Pancreatic β Cells. The recipient mice were anesthetized
with pentobarbital sodium at 50 mg/kg and were placed in anatomical mi-
croscope. Then 5 × 105 β cells transfected for 6 min with the pWPT plasmid
expressing CD31 or GFP were collected and grafted into the capsule of the left
kidney of the recipient mice. One hundred microliters of Vetergesic Multidose
(0.3 mg/mL) (Alstoe Animal Health) were given for postoperative analgesia.
Statistical Analysis. Results are expressed as mean ± SD or SEM, as indicated.
The Student’s t test and ANOVA were used. All reported P values are two-
sided. A P value of less than 0.05 was regarded as significant.
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